Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 3Phase 1/2 3Phase 3 2Phase 2/3 2Phase 1 1

Status

Recruiting 6Active not recruiting 5Not yet recruiting 3Completed 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid 1Burkitt Lymphoma 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9venetoclax 7toripalimab 7pembrolizumab 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7irinotecan sucrosofate 6Temozolomide 6Fluorouracil 6tislelizumab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5HMPL-013 5Etoposide 5Dexamethasone 5Cisplatin 5Carboplatin 5Capecitabine 5Biopsy 5sintilimab 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × blinatumomab × Clear all
NCT07604233 2026-05-22

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT07387926 2026-05-19

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Novartis

Phase 1/2 Not yet recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07313852 2026-04-20

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center

Phase 1/2 Not yet recruiting
26 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡